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For the last 60 years the mainstay of treatment for people with psychotic illness has been 
antipsychotic drugs1. Antipsychotics, however, are not usually fully effective, and are 
associated with side-effects, ranging from weight gain/metabolic syndrome to the 
irreversible movement disorder of tardive dyskinesia. The last twenty years have therefore 
seen exploration of possible benefits of modern psychological interventions, the most 
studied being cognitive behavioural therapy (CBT), examined in at least 50 trials2, and 
currently recommended by NICE.3 
 
In the COMPARE trial, Professor Morrison and colleagues conducted a feasibility 
randomised controlled trial (RCT) of CBT versus antipsychotic monotherapy, and 
combination of both antipsychotics and CBT, in predominantly people with first episode 
psychosis (FEP). The trial follows their similar trial of CBT in people with established 
schizophrenia, who refused antipsychotic treatment4. In the earlier study the authors 
concluded it was, “a preliminary trial, which needs to be followed up by a larger, pragmatic 
multicentre study”, accepting it was not designed to test effectiveness, some of the CBT 
group going on to take antipsychotics.5 
 
In the current study they recruited 75 people with predominantly FEP, not receiving 
treatment for at least 3 months. Prior antipsychotic treatment is unclear.  
Participants were given either up to 26 weekly CBT as monotherapy, antipsychotic 
monotherapy (varying doses, as per clinical practice) or a combination of both, for 6 
months. Primary outcomes were feasibility and PANSS total scores at one year. Statistical 
modelling revealed a significantly worse outcome for CBT monotherapy compared to 
combined intervention, and trend towards worse outcome for antipsychotic monotherapy. 
The authors report no appreciable increase in serious adverse events, and less side effects 
in the CBT group (though acknowledge this was due to improvement in the scale for the CBT 
group, as opposed to worsening in those treated with antipsychotics).  
 
Methodologically, it is unclear how people were diagnosed with psychosis (it seems 
significant numbers were included by virtue of attending FEP services), and no substance 
misuse history was reported. This raises issues of heterogeneity- treatment response and 
symptom fluctuations vary, especially in FEP, and with substance misuse. Some people may 
not require long-term antipsychotics (or much input at all), e.g. those with transient 
psychotic symptoms. This is reflected in the as-treated analysis, 5/13 people receiving no 
intervention having symptomatic response.  With no psychosocial placebo, it is difficult to 
tease out effects in the CBT monotherapy group. 
 
What is puzzling is how badly all groups fared. Meta-analysis of over 50 studies6 suggests 
58% of people with FEP achieve functional and symptomatic remission (symptomatic 
remission being eight PANSS items rated “mild or better.”) Here, response criteria was >50% 
improvement in PANSS total7, which, if anything gives higher response rates than 
symptomatic remission7. The as-treated analysis (Table 5) shows 0/21 antipsychotic 
monotherapy, 6/20 (CBT monotherapy) and 4/21 (combined) people fulfilled response 
criteria at one year- around 16%.  
A possible clue is that it is unclear how many people prescribed antipsychotics were actually 
concordant– self-report (used in this trial) is not accurate, a good example being significant 
numbers of people attending services for treatment resistant psychoses having 
undetectable blood antipsychotic levels7. In addition, antipsychotic doses appear not to 
have increased, despite non-response, and clozapine was not considered in anyone, despite 
clinical guidelines on this.1,8 
It appears we may therefore be lacking a valid active control group, and no psychosocial 
placebo group to measure possible non-specific effects of therapy, and symptom 
fluctuations. 
The authors should be congratulated on recruiting to target, demonstrating a trial like this is 
possible within the NHS.  
 
Where do we go from here? 
It would constitute what some may consider a Kuhnian paradigm shift for people with first 
onset psychosis, experiencing significant symptoms, not to be offered antipsychotic 
treatment, evidence for this versus placebo dating back to the initial NIMH trial9. Reducing 
duration of untreated psychosis was one of the drivers behind FEP services, early 
antipsychotic treatment the cornerstone of early intervention, before formalised 
psychosocial interventions11. Therefore, any alternatives need solid evidence before a larger 
trial is considered. 
 
If symptomatic response for those assigned antipsychotics was comparable to most FEP 
studies, if we knew people were actually taking antipsychotics, and no worse an outcome 
was seen for CBT monotherapy, a larger, similar study in FEP would have been the logical 
next step. 
 
Given the above, a more cautious approach should be considered- it would make sense for a 
larger, multi-centre trial along similar lines to the 2014 trial to take place, with addition of a 
psychological placebo, suggested in a commentary on that trial10 . We would then be in a 
position to evaluate the highly relevant question of effectiveness of CBT in people not taking 
antipsychotic medication, laying a foundation for further study, along the lines proposed by 
Morrison et al. 
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